semaglutide free speech Novo Nordisk's Ozempic® pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US Wegovy® Pill Guide and Dosing

Both are touted as effective ways to boost metabolism, increase energy, and accelerate fat loss

Due to these significant and reproducible results and because of the economic impact of the North American weight loss industry ($USD145.57 billion per year [$CAD197.9 billion]), semaglutide received nine million prescriptions in the United States within the last quarter of 2022, resulting in medication shortages expected to last well into 2024

Ozempic lowers the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes who also have chronic kidney disease

In November 2023, the FDA granted approval for tirzepatide under the brand name Zepbound for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity